Detail akcie X4 Pharma Rg online

Business Summary: X4 Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on discovering and developing novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. Its lead clinical candidate is mavorixafor, a small-molecule selective antagonist of chemokine receptor CXCR4. It has developed a small-molecule, oral antagonists of the chemokine receptor C-X-C receptor type 4 (CXCR4). It has two pre-clinical candidates: X4P-003, a second-generation CXCR4 antagonist designed to have enhanced properties relative to mavorixafor, potentially enabling opportunities in CXCR4-dependent disorders and primary immunodeficiencies, and X4P-002, a CXCR4 antagonist with a distribution profile and a demonstrated ability to cross the blood-brain barrier.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, X4 Pharmaceuticals Inc revenues increased from $1.1M to $32.5M. Net loss totaled $55.3M vs. income of $2.4M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net loss reflects Discovery, Development and commercialization of novel therap segment loss increase from $686K to $27.5M.